Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.transgenebiotek.com | |
Market Cap | 21.82 Cr. | |
Enterprise Value(EV) | 34.13 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | -1.10 | Trailing Twelve Months Ending 2022-09 |
Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2022-09 |
Industry PE | 46.72 | Trailing Twelve Months Ending 2022-09 |
Book Value / Share | 1.88 | Trailing Twelve Months Ending 2022-09 |
Price to Book Value | 1.53 | Calculated using Price: 2.88 |
Dividend Yield | 0.00 | Period Ending 2022-03 |
No. of Shares Subscribed | 7.58 Cr. | 75,770,000 Shares |
FaceValue | 10 | |
Company Profile | ||
Transgene Biotek Ltd (TBL) was set up in 1991, and was probably the first true Biotechnology Company in India. It is listed on the Indian Stock Exchanges and is involved in the development of several cutting edge technologies. |
1 Day |
|
+1.05% |
1 Week |
|
+1.41% |
1 Month |
|
-1.71% |
3 Month |
|
-7.40% |
6 Month |
|
-15.54% |
1 Year |
|
-19.55% |
2 Year |
|
-25.19% |
5 Year |
|
+21.52% |
10 Year |
|
-21.74% |
9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | -50.54 | -9.63 | -11.78 | -17.03 | -11.57 | -18.31 | -28.73 | -38.00 | -52.52 | |
Return on Capital Employed (%) | -47.36 | -8.84 | -10.85 | -14.68 | -6.74 | -14.83 | -22.10 | -26.55 | -32.32 | |
Return on Assets (%) | -36.70 | -5.45 | -6.56 | -7.77 | -3.35 | -4.84 | -6.39 | -6.45 | -6.84 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | 206 | 191 | 174 | 59 | 52 | 44 | 33 | 22 | 17 | 14 | |
Non Curr. Liab. | 127 | 127 | 127 | 127 | 120 | 120 | 120 | 120 | 121 | 121 | |
Curr. Liab. | 26 | 25 | 11 | 12 | 14 | 13 | 14 | 14 | 9 | 10 | |
Minority Int. | |||||||||||
Equity & Liab. | 358 | 344 | 313 | 198 | 187 | 177 | 167 | 157 | 147 | 145 | |
Non Curr. Assets | 338 | 326 | 310 | 197 | 186 | 176 | 166 | 156 | 146 | 144 | |
Curr. Assets | 20 | 18 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 358 | 344 | 313 | 198 | 187 | 177 | 167 | 157 | 147 | 145 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09 Rs. Cr. TTM |
Net Sales | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
Other Income | 1 | 0 | 0 | 1 | 7 | 2 | 0 | 0 | 0 | 0 | |
Total Income | 2 | 0 | 0 | 1 | 7 | 2 | 0 | 0 | 0 | 0 | |
Total Expenditure | -3 | -2 | -1 | -3 | -2 | -1 | -1 | -1 | -1 | -1 | |
PBIDT | -1 | -2 | -1 | -2 | 5 | 1 | -1 | 0 | 0 | -1 | |
Interest | 0 | 0 | 0 | -1 | 0 | 0 | 0 | 0 | 0 | ||
Depreciation | -17 | -17 | -21 | -18 | -10 | -10 | -10 | -10 | -10 | -7 | |
Taxation | -1 | ||||||||||
Exceptional Items | -115 | ||||||||||
PAT | -133 | -19 | -22 | -20 | -6 | -9 | -11 | -10 | -10 | -8 | |
Minority Interest | |||||||||||
Share Associate | |||||||||||
Other Related Items | |||||||||||
Consolidated Net Profit | -133 | -19 | -22 | -20 | -6 | -9 | -11 | -10 | -10 | -8 | |
Adjusted EPS | -18 | -3 | -3 | -3 | -1 | -1 | -1 | -1 | -1 | -1 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 13 | -2 | 4 | 6 | 0 | -1 | -2 | 0 | 0 | 0 | |
Cash Fr. Inv. | -15 | 1 | -5 | -6 | 3 | 2 | 0 | 0 | |||
Cash Fr. Finan. | 2 | 1 | 1 | -2 | 0 | ||||||
Net Change | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
Cash & Cash Eqvt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Fri, 27 Jan 2023
Board Meeting Intimation for Board Meeting. TRANSGENE BIOTEK LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2023 inter alia to consider and approve This is to inform you that a Meeting of the Board of Directors will be held on Tuesday 14th February 2023 at 11.00 am to transact the following business:1) To consider and approve the unaudited standalone & consolidated financial results for the quarter ended on 31st December 2022 along with the Limited Review Report as provided by the Statutory Auditor of the Company. |
Thu, 12 Jan 2023
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Confirmation Certificate Details in the matter of Regulation 74(5) of SEBI (Depositories & Participants) Regulations 2018. |
Sat, 07 Jan 2023
Disclosure Of Related Party Transactions Under Regulation 23(9) Of SEBI (LODR) Regulations 2015. Disclosure of Related Party Transactions under Regulation 23(9) of SEBI (LODR) Regulations 2015. |
Wed, 25 Jan 2023 |
|
|
|
Tue, 24 Jan 2023 |
|
|